8-K: Firefly Neuroscience Secures $2.25M in Initial Funding

Firefly Neuroscience, Inc. announced an initial $2.25 million private placement with accredited investors, including warrants and potential for an additional $18 million.

Summary

• Firefly Neuroscience, Inc. entered into a Securities Purchase Agreement on March 8, 2026, with accredited investors.
• The company completed an initial closing on March 12, 2026, raising $2,250,000 through the sale of 1,500,000 units at $1.50 per unit.
• Each unit consists of either one share of common stock or a pre-funded warrant (exercise price $0.0001), one 150% common stock purchase warrant (exercise price $1.88), and one 200% common stock purchase warrant (exercise price $2.50).
• Investors have the right, but not the obligation, to purchase up to an additional $18,000,000 in units within 30 days of the initial closing.
• The offering was structured to comply with Nasdaq Listing Rule 5635(d) to avoid requiring stockholder approval.
• The company will file a registration statement on Form S-1 by April 15, 2026, to cover the resale of the shares and warrant shares.
• Investors are subject to a six-month lock-up period until September 12, 2026, followed by a six-month leak-out period until March 12, 2027, during which 1/6th of their securities will be released monthly.
• Proceeds from the sale of units will be used for general corporate and working capital purposes, and to cover issuance-related fees and expenses.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. While the capital raise provides essential funding and signals investor confidence, the significant potential for future dilution from the warrants warrants a cautious optimism.

Positives

• Secured an initial $2.25 million in funding, providing immediate capital.
• Potential for an additional $18 million in investment from existing accredited investors within 30 days, indicating investor confidence and significant future funding potential.
• The transaction was structured to comply with Nasdaq Listing Rule 5635(d), avoiding the need for potentially time-consuming and uncertain shareholder approval.
• The company has committed to filing a registration statement (Form S-1) by April 15, 2026, to facilitate the resale of shares and warrant shares, which is beneficial for investor liquidity.
• The lock-up and leak-out provisions for investors suggest a commitment to orderly market conditions post-investment, preventing immediate large-scale selling pressure.

Negatives

• The issuance of units, including common stock and multiple warrants, will result in significant dilution for existing shareholders upon exercise of the warrants.
• The pre-funded warrants have a nominal exercise price of $0.0001, meaning the majority of the purchase price was paid upfront, but the shares will still be issued, increasing the share count.
• The exercise prices of the 150% Warrants ($1.88) and 200% Warrants ($2.50) are relatively low compared to the unit purchase price of $1.50, suggesting the potential for immediate profit for investors if the stock price rises above these levels, leading to further dilution.
• The company has reserved 40,500,000 shares for issuance from these warrants, which is a substantial number compared to the 14,282,511 shares outstanding as of January 27, 2026, indicating potential for significant future dilution.

Risks

• Dilution Risk: The issuance of common stock and multiple warrants, particularly the pre-funded warrants and the 150% and 200% warrants, will lead to substantial dilution for existing shareholders upon their exercise.
• Market Price Volatility: The value of the warrants is tied to the company's common stock price, making the investment susceptible to market fluctuations.
• Registration Statement Effectiveness: While the company committed to filing an S-1 registration statement, there is a risk it may not become effective within the targeted 45 or 90 calendar days, or at all, which could impact investor liquidity.
• Future Selling Pressure: After the lock-up period ends on September 12, 2026, and during the subsequent leak-out period until March 12, 2027, investors will gradually be able to sell their shares, potentially creating selling pressure on the stock.
• Failure to Secure Additional Investment: The additional investment of up to $18 million is optional for investors, and there is no guarantee it will be fully subscribed, which could limit the company's total capital infusion.
• Nasdaq Compliance: The company must ensure continued compliance with Nasdaq listing rules, including the Exchange Cap Limitation, which could restrict warrant exercise if shareholder approval is not obtained.

Future Outlook

The company plans to use the net proceeds from the offering for general corporate and working capital purposes. It is committed to filing a registration statement on Form S-1 by April 15, 2026, to enable the resale of the newly issued shares and warrant shares, aiming for effectiveness within 45 to 90 days depending on SEC review. Investors also have the option to provide up to an additional $18 million in funding within 30 days of the initial closing.

Management Comments

• The Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated. By: Name: Greg Lipschitz Title: Chief Executive Officer

Industry Context

StockSavvy.ai notes that this capital raise provides Firefly Neuroscience, Inc., a company in the neuroscience sector, with crucial funding for its operations and working capital. Such private placements are common for growth-stage companies, particularly in biotech or healthcare, to fuel research, development, or commercialization efforts. The structure with warrants and beneficial ownership limitations is typical for private investment in public equity (PIPE) deals, balancing investor upside with regulatory compliance and avoiding immediate shareholder approval.

Comparison to Industry Standards

• The unit price of $1.50 and the warrant exercise prices ($0.0001, $1.88, $2.50) are specific to Firefly Neuroscience and cannot be directly compared to global benchmarks without more context on the company's valuation, stage of development, and market conditions.
• The beneficial ownership limitations (4.99% or 9.99%) are standard provisions in private placements to prevent investors from triggering certain reporting requirements or control thresholds.
• The lock-up and leak-out periods (6 months and 6 months, respectively) are common mechanisms to manage potential selling pressure from new investors in private placements, similar to those seen in IPOs or secondary offerings for other growth companies.
• The commitment to file an S-1 registration statement for resale is a standard practice in PIPE transactions to provide liquidity for investors, aligning with typical investor expectations in such deals.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience significant dilution upon the exercise of the newly issued warrants. The lock-up and leak-out periods aim to manage selling pressure, but future sales could still impact share price.
• Company: Receives immediate capital for operations and working capital, with the potential for substantial additional funding, strengthening its financial position.
• Investors: Gain equity and warrant positions with potential for upside, subject to lock-up restrictions and market performance.

Next Steps

• Company to file a registration statement on Form S-1 by April 15, 2026, for the resale of shares and warrant shares.
• Company to use best efforts to cause the registration statement to become effective within 45 to 90 calendar days after filing.
• Potential for investors to exercise their right to purchase up to an additional $18,000,000 in units within 30 days of the initial closing.
• Investors are subject to a six-month lock-up period until September 12, 2026, followed by a six-month leak-out period until March 12, 2027.
• Investors will vote in favor of increasing shares authorized for the 2024 Long-Term Incentive Plan up to 2,000,000 shares upon company request.

Key Dates

Recommendation

The capital raise provides essential funding for Firefly Neuroscience and signals investor confidence, which is a positive. However, the significant potential for dilution from the warrants, coupled with the relatively low exercise prices, introduces considerable uncertainty regarding future share price performance. The lock-up and leak-out periods mitigate immediate selling pressure but do not eliminate the long-term dilution risk. A 'hold' recommendation is appropriate as investors should monitor the company's use of funds, progress on its business objectives, and the impact of future warrant exercises on the stock price before making further investment decisions.

Keywords

Firefly Neuroscience, Private Placement, Securities Purchase Agreement, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, Dilution, SEC Filing, Nasdaq Listing Rule 5635(d), Lock-Up Agreement, Form S-1 Registration, Accredited Investors, AIFF